Concepedia

Author

Cyril P. Clarke

San Francisco VA Medical Center

Also Known As

C CLARKE, C.P. CLARKE, C.P. Clarke, Cyril Clarke, Cyril P Clarke, Cyril P. Clarke

12

Publications

742

Citations

7

H-Index

25

Concepts

All Affiliations

San Francisco VA Medical CenterCytokinetics (United States)University of ManchesterUniversity of California, San FranciscoManchester Academic Health Science Centre
CP

About

Cyril P. Clarke is an author at San Francisco VA Medical Center specializing in medicine, cardiology, and physiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

641

2

Health Sciences

1

1

10

3

Public Health

1

1

260

4

Social Sciences

1

1

28

5

Neuroscience

1

1

28

Cyril P. Clarke

×

7

Publications

723

Citations

7

H-Index

YearCitations

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

John G.F. Cleland, John R. Teerlink, Roxy Senior,

The Lancet

2011

329

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

John R. Teerlink, Cyril P. Clarke, Khalil G. Saikali,

The Lancet

2011

260

Evaluation of the analgesic efficacy and psychoactive effects of <scp>AZD</scp>1940, a novel peripherally acting cannabinoid agonist, in human capsaicin‐induced pain and hyperalgesia

Jarkko Kalliomäki, Peter Annas, Karin Huizar,

Clinical and Experimental Pharmacology and Physiology

2013

58

Brain Serotonin Transporter Occupancy by Oral Sibutramine Dosed to Steady State: A PET Study Using 11C-DASB in Healthy Humans

Peter S. Talbot, Stefan Bradley, Cyril P. Clarke,

Neuropsychopharmacology

2009

28

Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies

Clive Wilson, Cyril P. Clarke, Yan Yan L. Starkey,

Drug Development and Industrial Pharmacy

2011

24

The Selective Cardiac Myosin Activator, CK-1827452, Increases Left Ventricular Systolic Function by Increasing Ejection Time: Results of a First-in-Human Study of a Unique and Novel Mechanism

John R. Teerlink, Fady I. Malik, Cyril P. Clarke,

Journal of Cardiac Failure

2006

14

Abstract 2169: The Selective Cardiac Myosin Activator, CK-1827452, a Calcium-Independent Inotrope, Increases Left Ventricular Systolic Function by Increasing Ejection Time Rather than the Velocity of Contraction

Fady I. Malik, John R. Teerlink, Rafael Escandón,

Journal of Wildlife Diseases

2006

10

Page 1